SCHEMBL5006255

SCHEMBL5006255

CC1CCN(c2cc(C3CC(=O)NC(=O)C3)ccc2C(N)=O)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CTPS1 P17812 1/20 0.42
KDM4E B2RXH2 4/20 0.41
GAA P10253 4/20 0.41
HSD17B10 Q99714 2/20 0.41
POLB P06746 1/20 0.41
NR4A1 P22736 1/20 0.41
MAPT P10636 3/20 0.40
MAPK1 P28482 1/20 0.40
CDK8 P49336 1/20 0.40
CSF1R P07333 2/20 0.39
NPC1 O15118 2/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
HTT P42858 3/20 0.38
CDC7 O00311 1/20 0.38
CDK9 P50750 1/20 0.38
NR1I2 O75469 1/20 0.37
GRM2 Q14416 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5009210 0.86 HTT (0.50) ALDH1A1SMN1; SMN2KDM4EGAAHSD17B10
SCHEMBL3542135 0.84 CSF1R (0.52) ALDH1A1SMN1; SMN2CTPS1KDM4EGAA
SCHEMBL5006260 0.83 GAA (0.49) ALDH1A1SMN1; SMN2CTPS1KDM4EGAA
SCHEMBL5006309 0.82 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2CTPS1KDM4EGAA
SCHEMBL3539761 0.81 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2CTPS1KDM4EGAA
SCHEMBL3541922 0.81 CSF1R (0.53) ALDH1A1SMN1; SMN2CTPS1KDM4EGAA
SCHEMBL5009207 0.79 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2CTPS1KDM4EGAA
SCHEMBL16208957 0.77 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2CTPS1KDM4EGAA
SCHEMBL4341037 0.77 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2CTPS1KDM4EGAA
SCHEMBL16208919 0.77 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2CTPS1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296726-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-03-29 US disclosed
US-20150051196-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2015-02-19 US disclosed
US-8895584-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-11-25 US disclosed
US-20140243382-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-08-28 US disclosed
US-8759347-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US disclosed
US-20130281475-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2013-10-24 US disclosed
US-8481564-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2013-07-09 US disclosed
US-20080275031-A1 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent ILLIG CARL R 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281475-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES ALDH1A1 4702/4885SMN1; SMN2 2358/4885CTPS1 2563/4885
US-20150051196-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES ALDH1A1 4702/4885SMN1; SMN2 2358/4885CTPS1 2563/4885
US-20140243382-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES ALDH1A1 4702/4885SMN1; SMN2 2358/4885CTPS1 2563/4885
US-20080275031-A1 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent MUSK, CHUK, CAMK4 ALDH1A1 3802/4885SMN1; SMN2 1787/4885CTPS1 2868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.